Voorspelling daling/stijging plasma natrium
Formule voor berekening voorspelde daling of stijging van het plasma natrium per liter infuusvloeistof naar aanleiding van de gekozen infuusvloeistof.
Research authors: Adrogue HJ, and Madias NE
Version: 1.21
  • Public
  • Internal medicine
  • {{ modelType }}
  • Details
  • Validate model
  • Save input
  • Load input

Calculate the result

Set more parameters to perform the calculation

Voorspelde daling/stijging plasma natrium per liter infuusvloeistof: mmol/L

{{ resultSubheader }}
{{ chart.title }}
Result interval {{ additionalResult.min }} to {{ additionalResult.max }}

Conditional information

Aan de hand van deze formule kan de voorspelde daling of stijging van het plasma natrium (Na+) naar aanleiding van de gekozen infuusvloeistof worden ingeschat.


Referentie concentratie natrium in infuusvloeistof (in mmol per liter):

  • Glucose 5% bevat:                                               0 mmol natrium per liter.
     
  • NaCl 0,25% bevat:                                             34 mmol natrium per liter.
  • NaCl 0,45% bevat:                                             77 mmol natrium per liter.
  • NaCl 0,9% bevat:                                             154 mmol natrium per liter.
  • NaCl 2,5% bevat:                                             427 mmol natrium per liter.
  • NaCl 3,0% bevat:                                             513 mmol natrium per liter.
  • NaCl 5,0% bevat:                                             855 mmol natrium per liter.
     
  • Ringer lactaat bevat:                                        130 mmol natrium per liter.

  • NaBic 1.4% bevat:                                            167 mmol natrium per liter.
  • NaBic 4.2% bevat:                                            500 mmol natrium per liter.
  • NaBic 8.4% bevat:                                            1000 mmol natrium per liter.


Referenties:
Adrogue, HJ; and Madias, NE. Primary Care: Hypernatremia. New England Journal of
Medicine 2000; 342(20):1493-1499.

{{ file.classification }}
PRO
Note
Notes are only visible in the result download and will not be saved by Evidencio

This model is provided for educational, training and information purposes. It must not be used to support medical decision making, or to provide medical or diagnostic services. Read our full disclaimer.

Underlying models Part of
Comments
Comment
Please enter a comment
Comments are visible to anyone

Model feedback

No feedback yet 1 Comment {{ model.comments.length }} Comments
On {{ comment.created_at }} {{ comment.user.username }} a no longer registered author wrote:
{{ comment.content }}
logo

Please sign in to enable Evidencio print features

In order to use the Evidencio print features, you need to be logged in.
If you don't have an Evidencio Community Account you can create your free personal account at:

https://www.evidencio.com/registration

Printed results - Examples {{ new Date().toLocaleString() }}

Evidencio Community Account Benefits

With an Evidencio Community account you can:

  • Create and publish your own prediction models.
  • Share your prediction models with your colleagues, research group, organization or the world.
  • Review and provide feedback on models that have been shared with you.
  • Validate your models and validate models from other users.
  • Find models based on Title, Keyword, Author, Institute, or MeSH classification.
  • Use and save prediction models and their data.
  • Use patient specific protocols and guidelines based on sequential models and decision trees.
  • Stay up-to-date with new models in your field as they are published.
  • Create your own lists of favorite models and topics.

A personal Evidencio account is free, with no strings attached!
Join us and help create clarity, transparency, and efficiency in the creation, validation, and use of medical prediction models.

Disclaimer: Calculations alone should never dictate patient care, and are no substitute for professional judgement.
Terms & Conditions | Privacy Policy | Disclaimer | Contact | Refuse cookies |
Evidencio v3.25 © 2015 - 2024 Evidencio. All Rights Reserved